In a move to bolster its asset management division, Bank J. Safra Sarasin has announced the full acquisition of Zurich-based MIV Asset Management. This acquisition aligns with the Swiss-Brazilian private bank’s strategic focus on thematic equity investing, specifically in the growing medical technology (medtech) sector.
MIV Asset Management, founded in 1997, has long been recognized for its deep expertise in medical technology investments. Initially managing Microvalue, a firm specializing in medtech, MIV transitioned to the MIV Global Medtech Fund in 2008. Known for its innovative approach, MIV has a dedicated team of financial and medical technology analysts, making it a strong addition to J. Safra Sarasin’s portfolio.
With the acquisition, J. Safra Sarasin strengthens its position in a sector that is seeing rapid growth. The medtech industry is poised for expansion due to factors such as an aging global population, technological advancements, rising chronic diseases, and greater access to healthcare services in emerging markets. Additionally, artificial intelligence (AI) applications in the sector present significant long-term growth opportunities, which J. Safra Sarasin plans to capitalize on.
Although the financial terms of the deal have not been disclosed, this acquisition further demonstrates the bank’s commitment to growing its asset management business and enhancing its thematic investment strategies, particularly in the high-potential medtech field.
